Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche JB, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, De Vos J, Diana JS, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I

Bone Marrow Transplant. 2025 05 29;:

Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium.

Boyer O, Bensoussan D, Bönig H, Chabannon C, Clémenceau B, Cuffel A, Dachy G, de Vos J, Derenne S, Diana JS, Dougé A, Deramoudt L, Ferrand C, Forcade E, Galaine J, Galy A, Giverne C, Martinet J, Marton C, Larghero J, Reppel L, Viel S, Yakoub-Agha I, Deschamps M

Bone Marrow Transplant. 2025 01 25;:

Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T Cells.

Maino A, Amen A, Plumas J, Bouquet L, Deschamps M, Saas P, Chaperot L, Manches O

J Immunol. 2024 01 12;:

RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.

Bouquet L, Bôle-Richard E, Warda W, Neto Da Rocha M, Trad R, Nicod C, Haderbache R, Genin D, Ferrand C, Deschamps M

Gene Ther. 2023 05 12;:

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.

Nicod C, da Rocha MN, Warda W, Roussel X, Haderbache R, Seffar E, Trad R, Bouquet L, Goncalves M, Bosdure L, Laude MC, Guiot M, Ferrand C, Deschamps M

Curr Res Transl Med. 2023 02 4;71(2):103385

Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro.

Da Rocha MN, Guiot M, Nicod C, Trad R, Bouquet L, Haderbache R, Warda W, Baurand PE, Jouanneau C, Dulieu P, Deschamps M, Ferrand C

Immunol Res. 2022 12 2;:

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C

J Immunother Cancer. 2022 07;10(7):

[Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Rubio MT, Varlet P, Allain V, Ballot C, Cuffel A, Deschamps M, Ferrand C, Foguenne J, Forcade E, Huynh A, Guihot A, Latouche JB, Lemarie C, Martinroche G, Morin F, Nguyen S, Schmit K, Servais S, Simonetta F, Yakoub-Agha I, Caillat Zucman S

Bull Cancer. 2021 Jul 9;:

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.

Haderbache R, Warda W, Hervouet E, da Rocha MN, Trad R, Allain V, Nicod C, Thieblemeont C, Boissel N, Varlet P, Agha IY, Bouquet L, Guiot M, Venet F, Sujobert P, Roussel X, Rouzaire PO, Caillot D, Casasnovas O, Bories JC, Bachy E, Caillat-Zucman S, Deschamps M, Ferrand C

J Transl Med. 2021 Jun 21;19(1):265

Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.

Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, Roussel X, Nicod C, Deschamps M, Ferrand C

Cancer Gene Ther. 2021 Jan 7;:

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases.

Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, Limat S, Heyd B, Jary M, Loyon R, Borg C

J Immunother Cancer. 2020 Nov;8(2):

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.

Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F

Leukemia. 2020 Feb 28;:

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C

Front Oncol. 2020 ;10:599933

[Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Deschamps M, Decot V, Giverne C, Pinturaud M, Vaissié A, Parquet N, Olivero S, Anne-Claire M, Bay JO, Yakoub-Agha I, Ferrand C

Bull Cancer. 2019 Sep 20;:

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotévi O, Deschamps M, Ferrand C

Cancer Res.. 2018 Dec 4;:

Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y

Hum. Gene Ther.. 2018 Aug 23;:

Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M

Gene Ther.. 2016 Aug;23(8-9):664-72

Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma.

Wu T, Leboeuf C, Durand S, Su B, Deschamps M, Zhang X, Ferrand C, Pessaux P, Robinet E

Mol Med Rep. 2016 Mar;13(3):2645-54

The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.

Gamonet C, Deschamps M, Marion S, Herbein G, Chiocchia G, Auger I, Saas P, Ferrand C, Toussirot E

Rheumatology (Oxford). 2015 Sep;54(9):1744-5

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y

Int J Cancer. 2015 Jul 1;137(1):116-26

[New immunotherapeutic approches in oncology and hematology].

Kroemer M, Turco C, Galaine J, Deschamps, Borg C

Transfus Clin Biol. 2015 Jun 8. pii: S1246-7820(15)00031-2

Modeling of ray paths of head waves on irregular interfaces in TOFD inspection for NDE.

Ferrand A, Darmon M, Chatillon S, Deschamps M

Ultrasonics. 2014 Sep;54(7):1851-60

Incidence and risk factors of anti-HLA immunization after pregnancy.

Masson E, Vidal C, Deschamps M, Bongain S, Thevenin C, Dupont I, Rietmulher D, Pouthier F, Mongaillard G, Chabod J, Ferrand C, Tiberghien P, Rebibou JM

Hum Immunol. 2013 Aug;74(8):946-51

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C

Blood. 2010 Mar 25;115(12):2420-9